[go: up one dir, main page]

MA28011A1 - Derives de piperazine et leur utilisation en tant qu'agents therapeutiques - Google Patents

Derives de piperazine et leur utilisation en tant qu'agents therapeutiques

Info

Publication number
MA28011A1
MA28011A1 MA28839A MA28839A MA28011A1 MA 28011 A1 MA28011 A1 MA 28011A1 MA 28839 A MA28839 A MA 28839A MA 28839 A MA28839 A MA 28839A MA 28011 A1 MA28011 A1 MA 28011A1
Authority
MA
Morocco
Prior art keywords
therapeutic agents
piperazine derivatives
formula
mammal
methods
Prior art date
Application number
MA28839A
Other languages
English (en)
Inventor
Melwyn Abreo
Mikhail Chafeev
Nagasree Chakka
Sultan Chowdhury
Jian-Min Fu
Heinz W Gschwend
Mark W Holladay
Duanjie Hou
Rajender Kamboj
Vishnumurthy Kodumuru
Wenbao Li
Shifeng Liu
Vandna Raina
Sengen Sun
Shaoyi Sun
Serguei Sviridov
Chi Tu
Michael D Winther
Zaihui Zhang
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34120234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28011(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA28011A1 publication Critical patent/MA28011A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Des procédés de traitement d'une maladie ou d'une condition médiée par la SCD chez un mammifère, de préférence un humain, sont décrits, dans lesquels les procédés comprennent l'administration à un mammifère le nécessitant d'un composé de formule (I) : dans laquelle x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9, et R9a sont définis ci-dedans. Des compositions pharmaceutiques comprenant les composés de formule (I) sont également: décrites.
MA28839A 2003-07-30 2006-02-27 Derives de piperazine et leur utilisation en tant qu'agents therapeutiques MA28011A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US49109503P 2003-07-30 2003-07-30
US54681504P 2004-02-23 2004-02-23
US54689804P 2004-02-23 2004-02-23
US54693404P 2004-02-23 2004-02-23
US54678604P 2004-02-23 2004-02-23
US54682004P 2004-02-23 2004-02-23
US55341604P 2004-03-16 2004-03-16
US55349104P 2004-03-16 2004-03-16
US55340404P 2004-03-16 2004-03-16
US55340304P 2004-03-16 2004-03-16
US55344604P 2004-03-16 2004-03-16

Publications (1)

Publication Number Publication Date
MA28011A1 true MA28011A1 (fr) 2006-07-03

Family

ID=34120234

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28839A MA28011A1 (fr) 2003-07-30 2006-02-27 Derives de piperazine et leur utilisation en tant qu'agents therapeutiques

Country Status (23)

Country Link
US (1) US7335658B2 (fr)
EP (3) EP1648874B1 (fr)
JP (1) JP4808616B2 (fr)
KR (1) KR100934554B1 (fr)
AR (1) AR047557A1 (fr)
AT (1) ATE527242T1 (fr)
AU (2) AU2004261252C1 (fr)
CA (1) CA2533899C (fr)
CY (1) CY1112178T1 (fr)
DK (1) DK1648874T3 (fr)
EC (1) ECSP066313A (fr)
ES (2) ES2375134T3 (fr)
HK (1) HK1226399A1 (fr)
HR (1) HRP20110974T1 (fr)
IL (1) IL173395A (fr)
MA (1) MA28011A1 (fr)
NO (1) NO332822B1 (fr)
NZ (1) NZ545265A (fr)
PL (1) PL1648874T3 (fr)
PT (1) PT1648874E (fr)
TN (1) TNSN06034A1 (fr)
TW (2) TW201038270A (fr)
WO (1) WO2005011655A2 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US7390813B1 (en) * 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) * 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
TW201038270A (en) 2003-07-30 2010-11-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-CoA desaturase
US7514436B2 (en) * 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
SG145701A1 (en) * 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Piperazine derivatives and their use as therapeutic agents
MXPA06008201A (es) * 2004-01-23 2006-08-31 Amgen Inc Ligandos del receptor de vanilloide y su uso en tratamientos.
CN101090724A (zh) * 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
CA2580857A1 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
TW200626138A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CA2580855A1 (fr) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US8071603B2 (en) * 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515477A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
WO2006125179A1 (fr) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Composes tricycliques: utilisation comme agents therapeutiques
WO2007044085A2 (fr) * 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
WO2006125180A1 (fr) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Derives de piperazine: utilisation comme agents therapeutiques
EP2029138A1 (fr) * 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
RU2008103142A (ru) * 2005-07-01 2009-08-10 Новартис АГ (CH) Комбинация органических соединений
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
EP1966183A4 (fr) * 2005-12-20 2010-12-29 Merck Frosst Canada Ltd Composés hétéroaromatiques en tant qu'inhibiteurs de stéaroyl-coenzyme a delta-9 désaturase
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2007136746A2 (fr) * 2006-05-19 2007-11-29 Xenon Pharmaceuticals Inc. Composés macrocycliques et leurs utilisations en tant qu'agents thérapeutiques
PL2029572T3 (pl) 2006-06-05 2011-05-31 Novartis Ag Związki organiczne
MX2009002019A (es) 2006-08-24 2009-03-09 Novartis Ag Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
US8246433B2 (en) * 2006-08-25 2012-08-21 Alma Mater Sports, Llc Team based fantasy sport contest
WO2008056687A1 (fr) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
KR20090083477A (ko) * 2006-11-20 2009-08-03 그렌마크 파머수티칼스 에스. 아. 스테아로일-ＣｏＡ 불포화효소 저해제인 아세틸렌 유도체
WO2008096746A1 (fr) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited Composé spiro et son utilisation
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008104524A1 (fr) * 2007-02-28 2008-09-04 Smithkline Beecham Corporation Dérivés de thiadiazole, inhibiteurs de stéoryl-coa désaturase
ES2400710T3 (es) 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida
SI2148873T1 (sl) * 2007-04-23 2013-01-31 Janssen Pharmaceutica, N.V. Derivati 4-alkoksipiridazina kot antagonisti receptorja dopamina 2 s hitro disociacijo
UY31050A1 (es) 2007-04-27 2008-07-03 Shionogi & Co Antagonistas de trpv1 y usos de los mismos
CA2687964A1 (fr) 2007-06-01 2009-02-19 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies metaboliques de cellules hotes
WO2008157844A1 (fr) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Nouveaux dérivés de pipérazine en tant qu'inhibiteurs de stéaroyl-coa désaturase
CN104292144B (zh) 2007-08-08 2017-05-17 台晟医药有限公司 苯氧基吡咯烷衍生物及其应用和组合物
WO2009037542A2 (fr) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Composés spirocycliques en tant qu'inhibiteurs de stéaroyle coa désaturase
EP2197873B1 (fr) 2007-09-20 2014-07-16 Irm Llc Composés et compositions en tant que modulateurs de l'activité de gpr119
ES2528471T3 (es) 2007-12-11 2015-02-10 F. Hoffmann-La Roche Ag Inhibidores de la estearoil-CoA-desaturasa
US8895562B2 (en) * 2008-07-31 2014-11-25 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
AU2010215035B2 (en) 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2459568A4 (fr) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd Nouveaux composés spiro utiles en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
WO2011014520A2 (fr) 2009-07-29 2011-02-03 Irm Llc Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
EP2475367A1 (fr) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique Nouveaux inhibiteurs de stearoyl-coa-desaturase-1 et leurs utilisations
BR112012008004A2 (pt) 2009-10-09 2016-03-29 Irm Llc compostos e composições como moduladores da atividade de gpr119
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
WO2012176061A1 (fr) 2011-06-22 2012-12-27 Purdue Pharma L.P. Antagonistes de trpv1 comprenant un substituant dihydroxy et leurs utilisations
EP2766000A2 (fr) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Procédés d'utilisation d'antagonistes de scd1
WO2013144180A1 (fr) * 2012-03-28 2013-10-03 Intervet International B.V. Composés hétéroaryles à unité de pontage cyclique utilisés dans le traitement d'infections helminthiques
JP6293127B2 (ja) 2012-05-22 2018-03-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 未分化細胞の選択的阻害剤
WO2014052619A1 (fr) 2012-09-27 2014-04-03 Irm Llc Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
EA201890725A1 (ru) 2015-09-16 2018-08-31 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора и их применение
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
JP2020514293A (ja) 2017-01-06 2020-05-21 ユマニティ セラピューティクス，インコーポレーテッド 神経障害を治療する方法
PL3609888T3 (pl) 2017-03-15 2025-12-01 Eli Lilly And Company Agoniści receptora farnezoidowego X i ich zastosowanie
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
CA3083000A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composes et utilisations de ces composes
EP3768269B1 (fr) 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Composés et leurs utilisations
JOP20200282A1 (ar) * 2018-05-09 2020-11-08 Lg Chemical Ltd مركب جديد ينطوي على نشاط مثبط للإنتيروببتيداز
WO2020061113A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
AU2021239956A1 (en) 2020-03-18 2022-10-13 Eli Lilly And Company Formulations of a farnesoid X receptor agonist

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US667452A (en) * 1900-09-08 1901-02-05 John A Hendrickson Computing attachment for pumps.
US2985657A (en) 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
EP0354920A1 (fr) 1987-04-03 1990-02-21 The Upjohn Company Amino-9,10-secosteroides
CA1338012C (fr) 1987-04-27 1996-01-30 John Michael Mccall Amines possedant des proprietes pharmaceutiques
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5166147A (en) 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity
GB9019143D0 (en) * 1990-09-01 1990-10-17 Bp Chem Int Ltd Thixotropic compositions
EP0520292A1 (fr) 1991-06-19 1992-12-30 Hoechst Aktiengesellschaft Dérivés d'azétidinones chirales et leur utilisation comme agents de dopage dans des mélanges de cristaux liquides
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP4169368B2 (ja) * 1996-01-15 2008-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脈管形成阻害性ピリダジンアミン
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) * 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
WO1999000386A1 (fr) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Ligands du recepteur d4 de la dopamine
ATE229945T1 (de) 1998-03-19 2003-01-15 Upjohn Co Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
CN1329614A (zh) 1998-10-21 2002-01-02 武田药品工业株式会社 稠合的哒嗪衍生物、它们的制备方法和用途
EP1126833A4 (fr) 1998-10-29 2004-09-08 Trega Biosciences Inc Derives oxadiazole, thiadiazole et triazole et bibliotheques combinatoires contenant ces derives
EP1156045A4 (fr) 1999-01-28 2002-04-17 Nippon Shinyaku Co Ltd Derives d'amides et compositions de medicaments
PT1147112E (pt) 1999-01-29 2004-03-31 Abbott Lab Derivados diazabiciclicos como liganos nicotinicos do receptor de acetilcolina
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
WO2000061556A1 (fr) 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Composes heterocycliques contenant de l'azote et composes de benamide et medicaments contenant ces composes
JP3637961B2 (ja) * 1999-09-16 2005-04-13 田辺製薬株式会社 芳香族含窒素六員環化合物
US6677452B1 (en) 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
AU1887401A (en) 1999-12-14 2001-06-25 Nippon Shinyaku Co. Ltd. Medicinal composition
CA2398940C (fr) 2000-02-24 2012-02-21 Xenon Genetics, Inc. Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides
AU2001247372A1 (en) 2000-03-15 2001-09-24 Warner Lambert Company 5-amide substituted diarylamines as mex inhibitors
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
WO2002010154A2 (fr) * 2000-07-27 2002-02-07 Eli Lilly And Company Amides heterocycliques substitues
DE60134995D1 (de) 2000-09-26 2008-09-04 Xenon Pharmaceuticals Inc Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
DE10060412A1 (de) 2000-12-05 2002-06-06 Bayer Ag DELTA1-Pyrroline
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
CN1703401A (zh) * 2001-05-22 2005-11-30 神经原公司 黑色素浓集激素受体的配体:取代的1－苄基－4－芳基哌嗪类似物
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
CA2448298A1 (fr) 2001-06-15 2002-12-27 Yamanouchi Pharmaceutical Co., Ltd. Derive de phenylpyridinecarbonylpiperazine
US20050014942A1 (en) 2001-10-30 2005-01-20 Yasufumi Maruyama Amide derivatives and drugs
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
JP2005510564A (ja) 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
EP1456175A1 (fr) 2001-12-07 2004-09-15 Eli Lilly And Company Carboxamides heterocycliques substitues a action antithrombotique
MXPA04007612A (es) 2002-02-05 2004-11-10 Novo Nordisk As Aril- y heteroarilpiperazinas novedosas.
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
AU2003218738B2 (en) * 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
WO2003091247A2 (fr) 2002-04-25 2003-11-06 Pharmacia Corporation Acides piperidinylsulfonylmethylhydroxamiques et piperazinylsulfonylmethylhydroxamiques et leur utilisation comme inhibiteurs de protease
CA2493584A1 (fr) 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Augmentation de la sensibilite a l'insuline et traitement du diabete au moyen de l'inhibition de la stearoyl-coa desaturase 1 (scd1)
WO2004035549A1 (fr) 2002-10-17 2004-04-29 Amgen Inc. Derives de benzimidazoles et utilisation de ceux-ci en tant que ligands du recepteur vanilloide
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
TW201038270A (en) 2003-07-30 2010-11-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-CoA desaturase
SG145701A1 (en) 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Piperazine derivatives and their use as therapeutic agents
US7514436B2 (en) 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents

Also Published As

Publication number Publication date
NO20060981L (no) 2006-05-02
TW200518753A (en) 2005-06-16
JP2007500717A (ja) 2007-01-18
US20050065143A1 (en) 2005-03-24
NZ545265A (en) 2009-11-27
AR047557A1 (es) 2006-01-25
DK1648874T3 (da) 2012-01-23
HK1097256A1 (zh) 2007-06-22
EP2316827B1 (fr) 2016-01-27
HRP20110974T1 (hr) 2012-01-31
IL173395A0 (en) 2006-06-11
NO332822B1 (no) 2013-01-21
AU2004261252A1 (en) 2005-02-10
WO2005011655A3 (fr) 2005-03-24
ATE527242T1 (de) 2011-10-15
CA2533899C (fr) 2011-01-04
AU2009201788B2 (en) 2012-04-05
AU2004261252B2 (en) 2009-02-05
KR20060036107A (ko) 2006-04-27
PT1648874E (pt) 2011-12-23
EP3042895A1 (fr) 2016-07-13
ECSP066313A (es) 2006-07-28
KR100934554B1 (ko) 2009-12-29
PL1648874T3 (pl) 2012-04-30
EP1648874A2 (fr) 2006-04-26
WO2005011655A2 (fr) 2005-02-10
AU2009201788A1 (en) 2009-05-28
TNSN06034A1 (en) 2007-10-03
TWI345974B (en) 2011-08-01
CY1112178T1 (el) 2015-12-09
EP1648874B1 (fr) 2011-10-05
US7335658B2 (en) 2008-02-26
IL173395A (en) 2013-03-24
CA2533899A1 (fr) 2005-02-10
AU2004261252C1 (en) 2009-09-17
ES2375134T3 (es) 2012-02-27
HK1226399A1 (en) 2017-09-29
ES2568769T3 (es) 2016-05-04
EP2316827A1 (fr) 2011-05-04
TW201038270A (en) 2010-11-01
JP4808616B2 (ja) 2011-11-02

Similar Documents

Publication Publication Date Title
MA28011A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents therapeutiques
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
MA28012A1 (fr) Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques
TNSN06033A1 (en) Piperazine derivatives and their use as therapeutic agents
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
ATE491474T1 (de) Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists
MY144229A (en) Pyridazine derivatives and their use as therapeutic agents
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
DE69503760D1 (de) Kaliumsalz eines biphenylmethanderivates und dasselbe enthaltendes medikament
FR2833945A1 (fr) N-cyclopropylmethyl-azacycloalcanes, compositions les contenant et procedes de preparation
TH70458A (th) สารประกอบชนิดใหม่